Tag: $Novo Nordisk

Novo Holdings, parent of Novo Nordisk (NOVOb.CO), opens new tab, will buy contract drugmaker Catalent (CTLT.N), opens new tab for $11.5 billion in cash to help meet the strong demand for its popular weight-loss drug Wegovy, the companies said on Monday.

The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates to 232.3 billion kroner ($33.71 billion).

LONDON/COPENHAGEN, Nov 10 (Reuters) – Obesity drug maker Novo Nordisk said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.

Novo Nordisk reported a surge in earnings and revenue on Thursday as it continues to benefit from the popularity of its weight-loss drugs. However, the company is still struggling with raising the supply of the drugs to meet demand.

COPENHAGEN, Oct 16 (Reuters) – Novo Nordisk (NOVOb.CO) has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, from KBP Biosciences for up to $1.3 billion, the Danish drugmaker said on Monday.

Oct 10 (Reuters) – Novo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.

Novo Nordisk’s shares fell on Monday after financial news agency MarketWire reported that U.S. drug regulators had recently issued a report detailing quality control lapses at the group’s Clayton, North Carolina plant, citing sources.

Novo Nordisk, which makes blockbuster drug Wegovy, raised its outlook for 2023 Thursday but said it is extending supply restrictions for some doses of the weight-loss drug.

Shares of Danish drugmaker Novo Nordisk soared on Tuesday, after late-stage trial data showed that its obesity drug Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo.

Novo Nordisk on Sunday said a late-stage trial found that a high-dose oral version of its drug semaglutide helped overweight or obese adults lose 15% of their body weight, which is in line with recent results for other experimental obesity pills.

Novo Nordisk’s launch of obesity drug Wegovy in most of Europe will be slower than planned and the drug will likely not be sold in developing nations for a very long time, executives said on Tuesday, as demand booms in the United States.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs.